| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(11 years ago) | |
| US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(9 years ago) | |
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(2 years from now) | |
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(2 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(6 years from now) | |
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(6 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(9 years from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(10 years from now) | |
Aubagio is owned by Sanofi Aventis Us.
Aubagio contains Teriflunomide.
Aubagio has a total of 8 drug patents out of which 2 drug patents have expired.
Expired drug patents of Aubagio are:
- US5459163
- US5679709
Aubagio was authorised for market use on 12 September, 2012.
Aubagio is available in tablet;oral dosage forms.
Aubagio can be used as treatment of patients with relapsing forms of multiple sclerosis, treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose.
Drug patent challenges can be filed against Aubagio from 31 October, 2023.
The generics of Aubagio are possible to be released after 04 August, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
Dosage: TABLET;ORAL
AUBAGIO family patents
